Carr B.I.2024-08-042024-08-04202197830307873709783030787363https://doi.org/10.1007/978-3-030-78737-0_27https://hdl.handle.net/11616/92135Ten areas of collaboration for improving our subject are suggested. They include (1) a common HCC database; (2) HCC database with geographic patient locations, to detect HCC hotspots; (3) a Middle East HCC biobank; (4) public health teaching and awareness to limit horizontal hepatitis transmission; (5) conferences for mutual education and to foster collaborations; (6) transnational clinical trials; (7) biosimilar fabrication to make new effective agents more affordable; (8) identifying barriers to early diagnosis; (9) quality of life awareness and assessment; and (10) identification of unmet needs in HCC management, including downstaging therapies, post-resection adjuvant therapy, HBV therapy to decrease HCC aggressiveness, biomarkers for low-AFP patients, and adoption of circulating tumor cell/fragment assays for liquid biopsy and radiotherapies for PVT treatment. © The Author(s), under exclusive license to Springer Nature Switzerland AG 2021. All rights reserved.eninfo:eu-repo/semantics/closedAccessBarriers to early diagnosisBiobankBiosimilar fabricationClinical trialsDatabaseGeographic hotspotsHCC conferencesSanitary practice educationBook Chapter40340610.1007/978-3-030-78737-0_272-s2.0-85159725106N/A